J1562 — Injection, immune globulin (vivaglobin), 100 mg
J1562 is a HCPCS Level II code for injection, immune globulin (vivaglobin), 100 mg. It belongs to the Drugs Administered Other Than Oral Method section. It was terminated on December 31, 2025 and is not valid on new claims.
This code has been terminated
CMS terminated J1562 on December 31, 2025. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for J1562
- Long descriptor
- Injection, immune globulin (vivaglobin), 100 mg
- Short descriptor
- Vivaglobin, inj
- Added
- January 1, 2007
- Terminated
- December 31, 2025
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J1562
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J1562 is not quite right, the correct code is very often within a few positions of it.
- J1554Injection, immune globulin (asceniv), 500 mg
- J1555Injection, immune globulin (cuvitru), 100 mg
- J1556Injection, immune globulin (bivigam), 500 mg
- J1557Injection, immune globulin, (gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg
- J1558Injection, immune globulin (xembify), 100 mg
- J1559Injection, immune globulin (hizentra), 100 mg
- J1560Injection, gamma globulin, intramuscular, over 10 cc
- J1561Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg
- J1566Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg
- J1568Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
- J1569Injection, immune globulin, (gammagard liquid/gammagard liquid erc), 500 mg
- J1570Injection, ganciclovir sodium, 500 mg
- J1571Injection, hepatitis b immune globulin (hepagam b), intramuscular, 0.5 ml
- J1572Injection, immune globulin, (flebogamma/flebogamma dif), intravenous, non-lyophilized (e.g., liquid), 500 mg
- J1573Injection, hepatitis b immune globulin (hepagam b), intravenous, 0.5 ml
- J1574Injection, ganciclovir sodium (exela), not therapeutically equivalent to j1570, 500 mg
Questions about J1562
What is HCPCS code J1562?
J1562 is a HCPCS Level II code for injection, immune globulin (vivaglobin), 100 mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J1562?
The CMS HCPCS file marks J1562 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is J1562 still valid?
No. J1562 was terminated on December 31, 2025 and should not be used on new claims.